Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-30
2006-05-30
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001000, C514S004300, C514S008100, C514S009100, C514S011400, C514S014800, C530S300000, C530S317000, C530S321000, C530S326000, C530S385000, C530S386000, C530S387100, C436S064000, C436S086000, C424S184100, C424S185100
Reexamination Certificate
active
07053041
ABSTRACT:
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin αvβ5antagonists. The αvβ5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of αvβ5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing αvβ5antagonists.
REFERENCES:
patent: 4517686 (1985-05-01), Ruoslahti
patent: 4578079 (1986-03-01), Ruoslahti
patent: 4589881 (1986-05-01), Pierschbacher
patent: 4614517 (1986-09-01), Ruoslahti
patent: 4661111 (1987-04-01), Ruoslahti
patent: 4683291 (1987-07-01), Zimmerman .
patent: 4792525 (1988-12-01), Ruoslahti
patent: 4879237 (1989-11-01), Rudslahti
patent: 4988621 (1991-01-01), Ruoslahti
patent: 5041380 (1991-08-01), Ruoslahti
patent: 5061693 (1991-10-01), Nutt
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5567693 (1996-10-01), Backer et al.
patent: 5575815 (1996-11-01), Slepian et al.
patent: 5849692 (1998-12-01), Jonczyk et al.
patent: 5866540 (1999-02-01), Jonczyk et al.
patent: 5968902 (1999-10-01), Scarborough et al.
patent: 5981478 (1999-11-01), Ruoslahti et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6204280 (2001-03-01), Gante et al.
patent: 0 578 083 (1993-06-01), None
patent: 0 770 622 (1997-05-01), None
patent: 89/06536 (1989-07-01), None
patent: 95/14714 (1995-06-01), None
patent: 95/28426 (1995-10-01), None
patent: 97/14716 (1997-04-01), None
Friedlander et al. Definition of Two Angiogenic Pathways by Distinct Alpha v Integrins. Science 270:1500-1502.
Collier et al. H-ras Oncogene-transformed Human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. The Journal of Biological Chemistry. 263(14):6579-6587.
Chen et al. Isolation and Characterization of a 70-kDa metalloprotease (gelatinase) that is elevated in rous sarcoma virus-transformed chicken embryo fibroblasts. Journal of Biological Chemistry. 266(8):5113-5121.
Amino acid database; Accession #Q90611.
Amino acid database, Accession #A28153.
Lazar et al. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology 8(3):1247-1252, Mar. 1988.
Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996,Nature Med., 2(5):529-533.
Brooks, et al., Integrin αvβ3 antagonist promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994,Cell, 79:1157-1164.
Clark, et al, Transient functional expression of αvβ3 on vascular cells during wound repair, 1996,Am. J Pathol., 148:1407-1421.
Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992,J. Cell. Physiol., 153:437-449.
Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992,Seminars in Cancer Biology, 3:57-63.
Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993,Int. J. Cancer, 55:1023-1028.
Haynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992,Cell, 69:11-25.
Lehmann, et al., A monoclonal antibody inhibitis adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins αvβ3, αvβ5 and αvβ6, 1994,Cancer Res.,54:2102-2107.
Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987,J. Biol. Chem.,262:17294-17296.
Folkman, et al., Angiogenesis, 1992,J. Biol. Chem.,267:10931-10934.
Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994,Intl. J. Cancer, 57:920-925.
Drake, et al., A antago nist of integrin αvβ3 prevent maturation of blood vessels during embryonic neovascularization, 1995,J. Cell Sci.,108:2655-2661.
Folkman, et al., Inhibition of angiogenesis, 1992,Cancer Bio.,3:89-96.
Aumailley, et al., Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin-fragment P1, 1991,FEBS, 291(1):50-54.
Choi, et al., Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA, 1994,J. Vasc. Surg.,19:125-134.
Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994,Circulation, 90(5):2203-2205.
Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996,Eur. J. Cancer, 32A(1):152-159.
Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken fibroblasts using gene family PCR: expression of the gelatinase increases upo n malignant transformation, 1994, Biochem J., 300:729-736.
Friedlander, et al., Definition of two angiogenic pathways by distint αv integrins, 1995,Science, 270:1500-1502.
Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIbβ3, αvβ3 and α5βI and in cell adhesion inhibition, 1994,Cell Adhes. Commun., 2(6):491-501.
Smith, et al., Interaction of integrins αvβ3 and glycoprotein IIb-IIIa with fibrinogen, 1990,J. Biol. Chem., 265:12267-12271.
Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells,Antibosy, Immunoconjugates, and Radiopharmaceuticals, 1991, 4(2):99-106.
Ossowski, et al., Experimental model for quantitative study of metastasis, 1980,Cancer Res.,40:2300-2309.
Klein, et al., Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells, 1993,Mol. Biol. Cell, 4:973-982.
Brooks, et al., “Subtractive Immunization Yields Monoclonal Antibodies that Specificaly Inhibit Metastasis”, J. Cell Biology, 122: 1351-1359 (1993).
Brooks et al., Requirement of Vascular Integrin Alpha v Beta 3 for AngiogenesisScience, 264: 569-571 (1994).
Brown, et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer”, Human Path., 26:86 (1995).
Cheng, et al., “Human Microvascular Endothelial Cells express Integrin-Related Complexes that Mediate Adhesion to the Extracellular Matrix”,J. Cell Physiol., 139: 275-286 (1989).
Cheresh, David A., “Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in Attachment to fibrinogen and von Willebnrand factor”, Proc. Natl. Acad. Sci., USA, 84: 6471-6475 (1987).
Davis, et al., “Identification of Endothelial Cell Vascular Formation”,J. Cellular Biochemistry, 51: 206-218 (1993).
Horton, Michael, “Current Ststus Review Vitronectin receptor: tissue specific expression or adaptation to culture?”, Int. J. Exp Path., 71: 741-759 (1990).
Janat, et al., “regulation of Vascular Smooth Muscle Cell Integrin Expression by Transforming Growth Factor beta 1 By Platelet-Derived Growth Factor-BB”, J. Cellular Physiol., 151: 588-595 (1992).
Nicosia, et al., “Rapid Communication: Inhibition of Angiogenesis in vitro by Arg-Gly-Asp-Containing Synthetic Peptide”, Am. J. Path., 138: 829-833 (1991).
Pasqualini, et al., “A study of the structure, function and distribution of beta 5 integrins using novel anti-beta 5 moniclonal antibodies”, J. Cell Science, 105; 101-111 (1993).
Pfaff, et al., “Selective Recognition of Cycl
Brooks Peter C.
Cheresh David A.
Friedlander Martin
Fitting Thomas
Harris Alana M.
McCarthy Michael J.
The Scripps Research Institute
LandOfFree
Methods and compositions useful for inhibition of α v... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions useful for inhibition of α v..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions useful for inhibition of α v... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532780